Form 4: Neurocrine CEO Gano's RSU Vesting and Tax Withholding

Neurocrine Biosciences CEO Kyle Gano reported the vesting of 2,927 restricted stock units and the withholding of 1,580 shares for tax obligations.

Summary

• Kyle Gano, CEO and Director of Neurocrine Biosciences Inc. (NBIX), reported changes in beneficial ownership.
• On January 31, 2026, 2,927 Restricted Stock Units (RSUs) vested, converting into 2,927 shares of common stock.
• These RSUs were part of an award granted on January 31, 2022, which vested incrementally over four years.
• Concurrently, 1,580 shares of common stock were withheld by the company at a price of $136.06 per share to cover tax withholding requirements related to the RSU vesting.
• No shares were sold by Mr. Gano in this transaction.
• Following these transactions, Mr. Gano directly beneficially owns 141,754 shares of Neurocrine Biosciences common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, slightly positive event, as it reflects the planned vesting of executive compensation, reinforcing management's long-term stake in the company. It does not indicate any significant operational or financial changes.

Positives

• The CEO's equity stake in the company remains substantial, indicating continued alignment with shareholder interests.
• The vesting of RSUs represents a planned compensation event for the executive.

Negatives

• No direct negatives are indicated by this routine compensation and tax withholding report.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• No notable quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax withholding are standard practices for executive compensation in the biotechnology and pharmaceutical industries, aligning executive incentives with long-term company performance. This routine transaction does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• This transaction is a standard equity compensation event for a senior executive.
• StockSavvy.ai observes that similar RSU vesting schedules and tax withholding practices are common across publicly traded companies, including peers like Biogen Inc. (BIIB) or Vertex Pharmaceuticals Inc. (VRTX), where executive compensation packages frequently include performance-based equity awards that vest over several years.

Stakeholder Impact

• Shareholders: Minimal direct impact, as it's a routine compensation event. It reinforces the CEO's equity alignment.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing beyond the completion of this scheduled RSU vesting.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Kyle Gano, CEO, Director, Form 4, SEC filing, insider transaction, restricted stock units, RSU vesting, stock ownership, tax withholding, equity compensation